NASDAQ: CRVSCorvus Pharmaceuticals Inc Stock
$1.48-0.03 (-1.99%)
Updated Apr 25, 2024
CRVS Price
$1.48
Fair Value Price
$0.23
Market Cap
$72.58M
52 Week Low
$1.00
52 Week High
$4.19
P/E
-2.64x
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.03M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$24M
Beta
0.92
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRVS Overview
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRVS ($1.48) is overvalued by 532.02% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRVS ($1.48) is not significantly undervalued (532.02%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRVS due diligence checks available for Premium users.
Be the first to know about important CRVS news, forecast changes, insider trades & much more!
CRVS News
Valuation
CRVS fair value
Fair Value of CRVS stock based on Discounted Cash Flow (DCF)
Price
$1.48
Fair Value
$0.23
Overvalued by
532.02%
CRVS ($1.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRVS ($1.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.64x
Industry
15.41x
Market
40.97x
CRVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
5.8x
CRVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRVS's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.7M
Profit Margin
0%
CRVS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$45.6M
Liabilities
$6.9M
Debt to equity
0.18
CRVS's short-term assets ($27.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRVS's short-term assets ($27.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.2M
Investing
-$2.3M
Financing
$0.0
CRVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRVS vs Biotech Stocks
Corvus Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.